Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest.
about
The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signallingPathological survivin expression links viral infections with pathogenesis of erosive rheumatoid arthritisThe antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAILCaspase proteolysis of the integrin beta4 subunit disrupts hemidesmosome assembly, promotes apoptosis, and inhibits cell migration.1,1-Bis(3'-indolyl)-1-(p-bromophenyl)methane and related compounds repress survivin and decrease gamma-radiation-induced survivin in colon and pancreatic cancer cellsRelationship between survivin expression and recurrence, and prognosis in hepatocellular carcinomaTRAIL in cancer therapy: present and future challenges.Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 ExpressionCaspases target only two architectural components within the core structure of the nuclear pore complex.Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex.PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling.Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin.Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-Troglitazone-induced Apoptosis in Prostate Cancer Cells Involve AMP-activated Protein Kinase.Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.Coassembled cytotoxic and pegylated peptide amphiphiles form filamentous nanostructures with potent antitumor activity in models of breast cancer.Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension.TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.The potential of antidiabetic thiazolidinediones for anticancer therapy.PPARgamma and Apoptosis in Cancer.PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.Minireview: nuclear receptors and breast cancerThiazolidinediones as anti-cancer agents.The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products.The metabolism of proline as microenvironmental stress substrate.Characterization of synergistic anti-cancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorigenesis in mice.Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis.Combined modality therapy with TRAIL or agonistic death receptor antibodies.PPAR gamma, bioactive lipids, and cancer progression.Proline dehydrogenase (oxidase) in cancer.Insights into the Link Between Obesity and Cancer.Selenoprotein W depletion induces a p53- and p21-dependent delay in cell cycle progression in RWPE-1 prostate epithelial cells.Tunicamycin enhances TRAIL-induced apoptosis by inhibition of cyclin D1 and the subsequent downregulation of survivin.Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells.Effect of ligand troglitazone on peroxisome proliferator-activated receptor gamma expression and cellular growth in human colon cancer cells.Breast cancer prognosis predicted by nuclear receptor-coregulator networks.Δ2-Troglitazone promotes cytostatic rather than pro-apoptotic effects in breast cancer cells cultured in high serum conditions.Vitamin C deficiency attenuates liver fibrosis by way of up-regulated peroxisome proliferator-activated receptor-gamma expression in senescence marker protein 30 knockout mice.Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole.Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells.Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1α and Inhibition of VEGFR2 and TRKA.
P2860
Q28087571-A0D318B7-5E0E-4103-A4C2-8751CA6B42A2Q28236801-1956A34D-494C-4AD1-B53E-07B626C3F8DAQ28478349-C5F90BFA-4237-4E48-A3F8-547CAA7FE9C3Q33643674-AABD65B0-9FD4-4916-BB66-F7774946CED6Q33748743-7734251D-21D5-4287-87D7-43CAEA7ECDF0Q34225286-340234A7-187A-4FAE-B358-D71C524FF48DQ34291312-573121A3-C057-4057-A441-0155A25AB1E1Q34464915-2CEA5C73-E535-4C40-9EB5-8805AB1A9CA8Q34467322-F1EBE979-0922-40A9-BDB7-E6705177F6E3Q34646527-5FF01819-778C-4D05-BAC2-F44EA4D495BAQ35458969-43F01A6C-477C-420F-B6F3-B8A94FA6EE8EQ35588447-9542179A-EDF5-48DF-AF6C-6C5DE35B7888Q36065205-0427532B-79FD-4A03-920D-5E519396E6BBQ36187022-941A70D8-C9BE-44EE-9CC3-423440AEF987Q36279390-7946F3B3-5256-489F-BF82-4D4652165351Q36340848-56F10642-9CCB-4EBB-A0D9-1CCAD2B0D71BQ36365504-0F7DD6E2-B0A7-4CDF-904A-6E8A21F75E22Q36568732-E726530F-12B2-466A-A4ED-DD77B56B813DQ36742811-A9F2392A-53D3-44BC-8B20-B65EA978D573Q36772391-62609E46-2DCD-440D-A85E-628A1710173CQ36971797-9C2BF245-8B33-460E-91A4-D100A08CC768Q37010188-7223C871-1467-4ECC-9648-78C0B6B929F2Q37211832-6DE9E647-C1DF-4768-9142-0A23E5243D35Q37216401-CF8D15F5-8370-468D-8BC5-4506398DC831Q37359195-BFB06DD2-120A-4707-B087-CE3F2AC3654CQ37480201-2A252D73-3883-44C6-80F7-195D3AED6082Q37832083-2B2300DD-636E-4932-A478-E985068D6458Q37971590-A8DA41D1-28DA-422C-84A0-F114E6F128DBQ38034142-F46D5B80-4AF0-457D-A58C-15742F201091Q39256853-F2D6D05F-9B2F-480F-9EAB-702FC6DBD080Q39484755-379352C4-AE49-4C7B-9295-2FD4DF8DAF15Q39869215-532C97AF-DA5C-4C41-8296-CEA2E8635C4AQ39872214-B9D0EB7C-33CE-4A7B-9013-2FF1A50F32ECQ40201153-0CC5EEF2-9AE0-40D7-9E21-3EC3851C7001Q41134904-F6E9E405-F3D4-418D-922A-709D210DE7FAQ42331869-8A01C453-4CB4-4021-9827-A08E1D311781Q43159399-9A8C94C9-8ED5-495A-B8B5-47BE8CAFBA12Q46809704-0C67F3C7-EE8A-4FDE-B56A-6EDFFC0885FDQ47129762-A573F871-4295-4D72-82D3-AAE2977C545EQ47136807-5A8BFF63-44D2-461C-8CE0-BDF3176617A3
P2860
Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Peroxisome proliferator-activa ...... ression and cell cycle arrest.
@en
type
label
Peroxisome proliferator-activa ...... ression and cell cycle arrest.
@en
prefLabel
Peroxisome proliferator-activa ...... ression and cell cycle arrest.
@en
P2093
P2860
P356
P1476
Peroxisome proliferator-activa ...... pression and cell cycle arrest
@en
P2093
Bethany Freedman
Chunjiang Yu
Eun-Jig Lee
Jennifer M Schafer
Meiling Lu
V Craig Jordan
Vincent L Cryns
P2860
P304
P356
10.1074/JBC.M411519200
P407
P577
2004-11-29T00:00:00Z